Court Battle Over Mifepristone Could Reshape Telehealth Abortion Access
The 5th Circuit is weighing a challenge to FDA regulations on mifepristone, a drug used in most U.S. abortions and increasingly via telemedicine. The case is one of several legal fights that could restrict pharmacy and mail distribution, even as other courts push for fewer restrictions. An FDA safety review adds another layer of uncertainty for continued access.
The Louisiana case is one of three active challenges to FDA's mifepristone regulations, with separate suits from Florida/Texas and Missouri/Idaho/Kansas targeting earlier agency actions. A Louisiana district court had paused proceedings while the FDA conducts its own safety review, a decision the 5th Circuit panel is now reconsidering.
Mifepristone's regulatory history includes a 2011 REMS requirement for in-person dispensing, temporarily lifted by courts in 2020 and formally removed in the 2023 REMS amendment. The drug accounts for roughly 63% of U.S. abortions, with telemedicine now representing about 28% of abortion care. Meanwhile, provider groups have separately argued FDA restrictions remain excessively burdensome.
A ruling against the 2023 REMS could disrupt pharmacy and mail distribution of mifepristone nationwide, affecting patients in states where abortion remains legal as well as those traveling across state lines. Telehealth abortion patients, who now represent roughly a quarter of all abortion care, may face sudden changes in how they access medication. The FDA's parallel safety review adds uncertainty, as agency action could independently alter access regardless of court outcomes. Providers and patients may need to adapt quickly to shifting regulatory terrain.